A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
A phase 2 trial of Telotristat ethyl in Biliary tract cancer and Biliary tract cancer, run by TerSera Therapeutics LLC, recorded as terminated on the registry.
Overview
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT03790111 by TerSera Therapeutics LLC, with 53 participants recorded, started 2019-03-13 and due to reach its primary completion in 2022-01-13. Interventions recorded: telotristat ethyl. Conditions recorded: Biliary Tract Cancer (BTC).
Linked to the drug Telotristat ethyl because the registry names it among its interventions and Biliary tract cancer and Biliary tract cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTelotristat With Lutathera in Neuroendocrine Tumors
Shares Telotristat ethyl and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialCombination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.